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Abstract Objective: To define cases of chronic lymphocytic
leukemia (CLL) by immunophenotypic criteria and describe
the associated clinical features in patients diagnosed at Aga
Khan University Hospital, Nairobi.
Background: Rising to the growing cancer challenge will
require improved diagnostic services. CLL is common in
elderly patients. The current international standard in diag-
nosis incorporates findings of immunophenotyping. Facili-
ties for immunophenotyping have generally been unavail-
able in Kenya.
Method: A cross-sectional survey was conducted between
August 2011 and April 2012. Potential cases were identified
based on morphologic criteria. Consecutive samples were
obtained and subjected to 3 colour immunophenotyping on
a Cytomics FC 500 cytometer. CLL was defined using the
Royal Marsden Hospital scoring system. Baseline clinical
and diagnostic data were also obtained.
Results: Forty nine cases met the eligibility criteria. Thirty
one were known CLL cases, and 18 were newly diagnosed.
Median age at diagnosis was 62 years. Male:female ratio
was 1.3:1. Black patients (42/49) were more likely to pres-
ent with high risk disease (Rai stages III–IV) and with
higher lymphocyte counts than non-blacks at diagnosis.
Twenty six point five percent of patients in this study
were diagnosed in Rai stage 0. The prevalence of CD5/
CD23 co-expression was found to be 95.9%. CD5 was uni-
versally expressed, whereas CD23 was present in all but
2 cases. Both were associated with atypical morphology.
Complete absence of light chain expression using a mono-
clonal antibody was found in 12.2% of cases. Five patients
had their diagnosis revised. Of 31 patients on follow-up for
CLL, only 5 had had any form of immunophenotyping
done.
Keywords Immunophenotyping · Clinical features · CLL ·
Kenya
Résumé Objectif : Définir des cas de la leucémie lym-
phoïde chronique (LLC) selon les critères immunophéno-
typiques et décrire les caractéristiques cliniques associées
aux patients diagnostiqués à l’hôpital universitaire d’Aga
Khan de Nairobi.
Contexte : Combattre l’accroissement du cancer nécessite les
services diagnostiques avancés. La LLC est fréquente chez
les âgés. Une étude de l’immunophénotype, dont la capacité
manque généralement au Kenya, est recommandée pour son
diagnostic.
Méthode : Une enquête transversale fut faite entre août 2011
et avril 2012. Les échantillons des cas potentiels, selon les
critères morphologiques, furent collectionnés et soumis à la
cytométrie en flux 3 couleurs utilisant le cytomètre Cytomics
FC 500. La LLC était définie par le Score Royal Marsden
Hospital. Les données de base cliniques et diagnostiques fur-
ent aussi prises.
Résultats : Quarante-neuf cas furent inclus dont 31 déjà
diagnostiqués et 18 de nouveaux cas. L’âge médian au diag-
nostic était de 62 ans. Le ratio homme/femme était 1,3/1. Les
patients noirs (42/49) présentaient au diagnostic une maladie
plus avancée (stades III–IV de Rai) et une lymphocytose
plus élevée que chez les non-Noirs. 26,5 % des patients pré-
sentaient un stade 0. Tous les cas exprimaient le CD5. Tous
exprimaient le CD23, sauf deux qui montraient une morpho-
logie atypique : 95,9 % avaient le double marquage CD5/
CD23, 12,2 % n’exprimaient pas des chaînes légères. Le
diagnostic de cinq patients fut révisé. Seuls 5 des 31 patients
avaient déjà profité d’une étude de l’immunophénotype.
Mots clés Immunophénotype · Caractéristiques cliniques ·
LLC · Kenya
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Introduction
The 2008 International Workshop on chronic lymphocytic
leukemia (CLL) criteria and the 4th edition of the WHO
classification of hematolymphoid neoplasms incorporate
immunophenotyping results into the diagnostic criteria
for CLL [1,2]. A combined approach of immunopheno-
typing plus morphological evaluation improves diagnos-
tic accuracy and hence appropriate therapy and prognos-
tication [2,3]. CLL is known to occur in Kenya, but the
occurrence of CLL when accurately defined by morpho-
logical evaluation plus immunophenotyping has not been
described [4]. The typical CLL immunophenotype is a co-
expression of CD5 and CD23 in monoclonal B cells with
dim expression of surface immunoglobulin (sIg) and
absent/dim CD79b (or CD22), and the absence of expres-
sion of FMC7 [1,5]. The Royal Marsden Hospital (RMH)
scoring system, described by Matutes et al. [5] allows the
distinction between CLL (RMH = 3–5) and other B-cell
chronic lymphoproliferative disorders (RMH = 2 or less).
This study provides data on the diagnostic and clinical
features of CLL at a tertiary referral hospital in Kenya.
Methods
Study design
A cross-sectional survey was conducted between August
2011 and April 2012. Patients were recruited serially.
Study site
AKUH,N department of pathology. The department serves
the hospital plus a variety of outreach laboratories, indepen-
dent laboratories and hospitals spread across Kenya.
Study population
All patients with persistent lymphocytosis ≥ 3 months, con-
sistent morphology and who gave consent were eligible for
inclusion. Patients whose samples were unsuitable for
immunophenotyping or with inadequate supplementary clin-
ical information were excluded. Samples that obtained RMH
scores ≤ 2 were also excluded.
Procedure
Morphologic assessment was based on FAB criteria [6].
Cases were then categorized as typical or atypical morphol-
ogy based on a consensus diagnosis between 2 pathologists.
Consecutive samples were obtained and subjected to 3 colour
immunophenotyping on a Beckman Coulter Cytomics FC
500 cytometer. A limited panel of antibodies was used.
These included CD5, CD19, CD22, CD23, FMC7, kappa
and lambda. CLL was defined using the scoring system
described by Matutes et al. [5].
CD19 versus side scatter was the gating strategy used to
identify the B lymphocyte cluster. Histograms were evalu-
ated, and antigens were interpreted as positive/negative
and as dim/bright positive where the intensity of expres-
sion mattered. Antigen positivity was defined as reactivity
above isotype controls on > 20% of B cells as identified
by flow cytometry. Dim expression was defined when the
B-cell cluster fell within 1 decalogue of the isotope con-
trol. Bright positivity was when the cell cluster fell ≥ 2
decalogues of the isotope control [5]. Light chain restric-
tion (marker of clonality) was defined by an abnormal
kappa-lambda ratio of > 3:1 (kappa restricted) or < 1:2
(lambda restricted) [7]. Cases of CLL were defined as
those with a score of ≥ 3 [5]. The baseline clinical and
diagnostic data were also obtained. Approval for the
study was obtained from the institution’s research and
ethics committees.
Data management
Descriptive data are presented as tables, bar and pie charts.
Statistical differences in medians were sought using the
Mann–Whitney test. Differences in proportions were ana-
lyzed using the Chi Square (χ2) test. A P value <0.05 was
considered significant.
Results
A total of 49 patients were included in the final analysis.
Thirty one patients known to have CLL/SLL and 18 patients
with a new diagnosis of CLL/SLL were included. Of the
31 patients with an established diagnosis of CLL/SLL,
only 5 patients (16.1%) had had any form of immunopheno-
typing done. For patients already known to have the disease,
all the parameters recorded other than morphologic category
and immunophenotyping results were those found at base-
line. These patients were included since CLL is currently
considered an incurable disease and guidelines for diagnosis
mandate that immunophenotyping be performed as part of
the diagnostic workup (Table 1).
The mean, median and age range were 62.1, 62 and 45–
95 years, respectively (Fig. 1).
The majority of patients had a score of 5 and a minority
scored 3 which are similar to what is described [5,8].
The relative proportion of scores obtained was, however,
distorted by the fact that 6 cases were scored on 4 points
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only due to absence of detectable light chains. This
meant that the intensity of surface immunoglobulin (sIg)
expression could not be assessed and light chain restric-
tion could not be demonstrated. Five of these were
assigned a score of 4 and one was assigned a score of 3.
CD5 was universally expressed, CD23 positive in 47/49
and there was bright surface immunoglobulin (sIg) expres-
sion in 4/49 cases (Fig. 2) (Tables 2, 3).
Discussion
Twenty six point five percent of patients in this study were
diagnosed in Rai stage 0. In an earlier study on CLL in
Kenya, no patient (N = 42) was found to present with lym-
phocytosis only [4]. This may reflect the increased use of
automated complete blood counts. It may also point to an
increased number of patients undergoing routine full hae-
mogram as part of wellness checks. Similar trends have
been observed in developed countries where the majority
of their patients are now diagnosed as an incidental finding
[9,10].
The mean/median age was comparable to other African
series [12,13] but lower than that of developed nations
[11,14]. This may be explained by the life expectancy of
the population. The life expectancy in Africa is lower than
that in Europe or North America, and this may create a selec-
tion bias that could explain the clustering of diseases at an
earlier age. The youngest patient was 45 years old. An earlier
series, also done in Kenya, had documented that at least 4 of
42 patients were in the age bracket 15–39 years [4]. CLL at
that age is unusual [15] and their cases may represent rare
cases or may reflect misdiagnosis due to unavailability of
immunophenotyping facilities.
Racial differences were observed. It was noted that non-
blacks were more likely to present with earlier stage disease
and lower WBC counts than non-blacks and the difference
was statistically significant (Tables 4, 5). Though a similar
observation has been previously noted, the reason(s) for this
was not clear [16]. It could be that non-blacks had easier
access to health care.
CD5/CD23 co-expression was found in 95.9%. This
immunophenotype excludes most reactive or clonal lym-
phoid disorders that could be confused with CLL. It is also
reported to have a high positive predictive value in diag-
nosing CLL [8]. CD5 was found to be the most frequently
expressed marker with 100% of cases expressing it. CD23
was expressed in all but 2 cases. Six cases (12%) were
scored on 4 points only due to the complete absence of
detectable light chains. This aberrancy was attributed to
a genuine absence due to changes in the epitope targeted
by the monoclonal antibody used. The proportion of 12%
which was obtained is close to that seen by Horna et al.
Table 1 Baseline features at diagnosis.
Characteristic Number (%)
Gender (N = 49; M:F ratio =
1.3:1)
Male 28/49 (95% C.I 43.3–71%)
Female 21/49 (95% C.I 29–56.7%)
Race
African 42 (85.7)
Asian 4 (8.2)
Caucasian 3 (6.1)
Lymphadenopathy 29/49 (59.2)
Splenomegaly 25/49 (51.0)
Hepatomegaly 8/49 (16.3)
Presence of any B symptom 14/49 (28.6)
Night sweats 10/49 (20.4)
Weight loss 5/49 (8.5)
Extreme fatigue 1/49 (2.0)
Haemoglobin level (g/dL)
Mean = 11.4 (SD = 2.67)
< 11g/dL 18/49 (36.7)
≥ 11g/dL 31/49 (63.3
Thrombocytopenia (×109/L)
Mean=172.97 (SD = 85.01)
< 100 9/49 (18.4)
≥ 100 40/49 (81.6)
Absolute lymphocyte count
(×109/L)
Median = 40.5
Range (5.08–324.2)
Rai stage
0 13 (26.5)
I–II 17 (34.7)
III–IV 19 (38.8)
Binet
A 23 (46.9)
B 7 (14.3)
C 19 (38.8)
Fig. 1 Age distribution at diagnosis
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[17] who described the absence of light chain expression
in 13.2% of patients with CLL when a monoclonal anti-
body was used.
Of the 31 patients with an established diagnosis of CLL,
only 5 patients had had any form of immunophenotyping
done. This likely reflects the limited availability of these
services in Kenya. Five cases had their diagnosis revised
on the basis of morphologic and/or immunophenotypic cri-
teria (Table 6).
Conclusion
Immunophenotyping is diagnostically productive and
should be part of the diagnostic workup when a chronic lym-
phoproliferative disorder is suspected.
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Fig. 2 Frequency of RMH scores obtained
Table 2 Association between antigen expression patterns and morphologic subtype.
Antigen expression Typical, N (%) Atypical, N (%) χ2 P value
sIg Absent 6 (17) 0 (0) 3.39 0.18
Bright 2 (6) 2 (14)
Dim 27 (77) 12 (86)
FMC7 Absent/partial 32 (91) 12 (86) 0.36 0.55
Positive 3 (9) 2 (14)
CD22 Absent/dim 33 (94) 13 (93) 0.04 0.85
Bright 2 (6) 1 (7)
CD5/CD23 5+/23+ 35 (100) 12 (86) 5.21 0.02
5+/23- 0 (0) 2 (14)
Table 3 Association between treatment status, morphology and immunophenotype.
Treated Untreated P value
Morphology Typical 15 20 0.365
Atypical 8 6
sIga Absent 3 3 0.655
Bright 1 3
Dim 19 20
FMC7 Absent/partial 22 22 0.203
Positive 1 4
CD22 Absent/dim 23 23 0.093
Bright 0 3
CD5/CD23 CD5+/CD 23+ 23 24 0.174
CD5+/CD 23- 0 2
a sIg: surface immunoglobulin as evaluated using monoclonal antibodies against kappa and lambda immunoglobulin light chains.
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